Background-Dilated cardiomyopathy (DCM) is a heritable, genetically heterogeneous disorder that typically exhibits autosomal dominant inheritance. Genomic strategies enable discovery of novel, unsuspected molecular underpinnings of familial DCM. We performed genome-wide mapping and exome sequencing in a unique family wherein DCM segregated as an autosomal recessive (AR) trait. Methods and Results-Echocardiography in 17 adult descendants of first cousins revealed DCM in 2 female siblings and idiopathic left ventricular enlargement in their brother. Genotyping and linkage analysis mapped an AR DCM locus to chromosome arm 7q21, which was validated and refined by high-density homozygosity mapping. Exome sequencing of the affected sisters was then used as a complementary strategy for mutation discovery. An iterative bioinformatics process was used to filter Ͼ40 000 genetic variants, revealing a single shared homozygous missense mutation localized to the 7q21 critical region. The mutation, absent in HapMap, 1000 Genomes, and 474 ethnically matched controls, altered a conserved residue of GATAD1, encoding GATA zinc finger domain-containing protein 1. Thirteen relatives were heterozygous mutation carriers with no evidence of myocardial disease, even at advanced ages. Immunohistochemistry demonstrated nuclear localization of GATAD1 in left ventricular myocytes, yet subcellular expression and nuclear morphology were aberrant in the proband. Conclusions-Linkage analysis and exome sequencing were used as synergistic genomic strategies to identify GATAD1 as a gene for AR DCM. GATAD1 binds to a histone modification site that regulates gene expression. Consistent with murine DCM caused by genetic disruption of histone deacetylases, the data implicate an inherited basis for epigenetic dysregulation in human heart failure. (Circ Cardiovasc Genet. 2011;4:585-594.) The online-only Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/
I diopathic dilated cardiomyopathy (DCM) is a familial disorder in 20% to 48% of cases, 1-5 providing a rationale for screening echocardiography in at-risk relatives to detect presymptomatic disease. 6 Moreover, recognition of DCM as a heritable condition has been the impetus for human genetic investigations to uncover the molecular bases of myopathic heart failure. 7 Since 1993, pathogenic mutations in Ͼ30 genes have been identified in patients with DCM, yet mutations in these genes are estimated to account for only one third of cases. 6 The majority of DCM genes have been discovered by targeted DNA sequence analyses of candidate genes. However, a vast number of genes are expressed in the heart, and hypothesis-based approaches, by definition, cannot reveal unsuspected molecular underpinnings of disease.
Clinical Perspective on p 594
DCM gene mapping by genome-wide linkage analysis 8 offers a powerful alternative strategy, enabling discovery of novel, unanticipated disease genes. Furthermore, pathogenicity of a mutation can be robustly validated by demonstrating cosegregation with DCM. This approach is limited to rare, multigenerational families in which DCM segregates as a Mendelian, single-gene disorder. In suitable families, the ultimate success of linkage analysis largely depends on the physical size of the mapped chromosomal locus and the number of genes it comprises. To date, X chromosome and whole-genome linkage analyses have led to the identification of 1 gene for X-linked DCM 9 and 7 genes for autosomal dominant DCM, 10 -16 respectively. Each encoded protein has a distinct subcellular location in cardiac myocytes as follows: DMD, membrane-associated cytoskeleton; LMNA, nuclear membrane; TNNT2, thin filament of sarcomere; SCN5A, sarcolemma; TTN, sarcomeric cytoskeleton; EYA4, nucleus; MYH7, thick filament of sarcomere; and RBM20, spliceosome. Accordingly, the pathobiology of DCM as revealed by linkage studies is attributable to mutations that perturb contractile force generation and transmission, nuclear structure, ion homeostasis, and mRNA transcription and splicing.
Next-generation genomic technologies have emerged recently, providing unprecedented opportunities to complement and overcome inherent limitations of traditional DCM genediscovery strategies. Microarray-based comparative genomic hybridization 17 enables detection of aneuploidy (gains or losses of chromosomal material) with a resolution of Ϸ100fold higher than a conventional chromosome study. This molecular karyotype has become a routine clinical diagnostic tool and recently uncovered a large deletion in BAG3, encoding a co-chaperone of heat shock proteins, as a cause of DCM. 18 In 2009, advances in exon capture and massively parallel high-throughput DNA sequencing enabled scanning of the protein-coding regions of virtually all genes, which comprise Ϸ1% to 2% of the genome. 19 Several recent reports have highlighted the success of this powerful technique in identifying both known and novel molecular genetic bases for human disease. 20 In particular, exome sequencing has proven to be an efficient strategy for discovery of homozygous recessive mutations in unanticipated disease genes. 21 In the present study, we identified and phenotypically characterized a consanguineous family with nonsyndromic DCM, which segregated as an autosomal recessive trait. Linkage analysis, homozygosity mapping, and whole-exome sequencing were used as synergistic, large-scale genomic strategies to identify GATAD1 as a novel disease gene, thus implicating epigenetic perturbation as an underlying basis for human heart failure.
Methods

Study Subjects
Patients with DCM evaluated at Mayo Clinic since 1987 and their relatives were recruited for screening echocardiograms and molecular genetic investigations. We enrolled 273 unrelated probands, enriched for familial DCM (confirmed or suspected in 51%). The multigenerational family in the present study is white and of northern European ancestry by self-report. An ethnically matched group of 474 control subjects with normal echocardiograms was randomly selected from a community-based cohort. 22 Subjects provided written informed consent under a research protocol approved by the Mayo Clinic Institutional Review Board. Diagnostic criteria for DCM were as follows: lack of an identifiable cause for disease, left ventricular diastolic, systolic, or both dimensions Ͼ95th percentile as indexed for body surface area, 23 and left ventricular ejection fraction Ͻ50%. Idiopathic left ventricular enlargement was considered an intermediate phenotype of DCM, and individuals with left ventricular enlargement were classified as affected. 1, 4, 24, 25 Genomic DNA was isolated from peripheral blood white cells. Paraffin-embedded cardiac biopsy tissue from the proband was available for further analysis.
Linkage Analysis
Nineteen family members underwent genome-wide linkage analysis with the ABI PRISM Linkage Mapping Set HD5 version 2.5 (Applied Biosystems; Foster City, CA). Polymerase chain reactions were carried out using DNA samples and primer pairs that flanked 811 unique short tandem repeat markers. Amplified fragments were resolved on an ABI PRISM 3130xl, and genotypes were scored with GeneMapper Software (Applied Biosystems). Multipoint linkage analyses were performed with Simwalk2 version 2.91, 26 modeling recessive inheritance and specifying the following variables: phenocopy rate of 0.001, equal marker allele frequencies, and dichotomous liability classes (affected and unaffected). Secondary analyses were performed after reclassifying an individual with left ventricular enlargement as uncertain.
Homozygosity Mapping
The 9 children of consanguineous parents were genotyped using the Omni 1M Quad SNV (single-nucleotide variant) Chip (Illumina; San Diego, CA), with a mean call rate of 99.8%. A subset of 445 875 informative SNVs were analyzed with PLINK version 1.07 software (homozyg) 27 to identify genomic regions of homozygosity (Ն100 adjacent SNVs) shared among 3 affected siblings. Secondary analysis was performed to identify homozygous intervals present only in 2 affected sisters. Large-scale chromosomal abnormalities were screened for by analyzing B allele frequency plots as well as any areas where the log R ratio deviated from 0. Analysis also was performed using PennCNV 28 to identify copy number variation within the genome.
Exome Sequencing and Bioinformatics Analysis
Exome sequencing and variant annotation were performed using the Mayo Clinic Advanced Genomics Technology Center and Bioinformatics Core facilities. After exome capture with the SureSelect Target Enrichment System version 1.0 (Agilent; Santa Clara, CA), 76-bp paired-end sequencing was carried out on an Illumina GAIIx platform. The reads were aligned to human genome 36 (hg18). For mappable reads, Maq (Mapping and Assembly with Quality) was used for the detection of SNVs. 29 To identify insertions and deletions, a gapped alignment to the reference genome was tolerated by using Burrows-Wheeler Alignment 30 (see online-only Data Supplement, which details quality control for mapping and variant calling). SNVs were called within Maq, whereas insertions and deletions were called using the Genome Analysis Toolkit. 31 Allele frequencies were generated for known variants in the HapMap 32 and 1000 Genomes 33 databases. Classification and annotation of genetic variants was accomplished using both SIFT (Sorting Intolerant From Tolerant) 34 and SeattleSeq 35 software.
Mutation Scanning and Sanger Sequencing
Gene expression profiles were assessed by searching the Gene Expression Omnibus link on the National Center for Biotechnology Information Web site (www.ncbi.nlm.nih.gov), 36 analyzing data derived from Affymetrix GeneChip array data for 79 normal human tissues (GDS596), 61 normal mouse tissues (GDS592), and murine heart tissue at various stages of embryonic development (GDS627). Primer pairs were designed to encompass the 5 translated exons and flanking splice junctions of GATAD1 and 1 kb of 5Ј untranslated region, using Oligo Primer Analysis Software version 6.71 (Molecular Biology Insights; Cascade, CO). Polymerase chain reactionamplified products were treated with ExoSAP-IT (USB Corp; Cleveland, OH) and sequenced by the dye-terminator method using an ABI PRISM 3730xl DNA Analyzer (Applied Biosystems). The DNA sequences were viewed and analyzed with Sequencher version 4.5 (Gene Codes Corp; Ann Arbor, MI) DNA analysis software.
Each exon was evaluated for heterozygous sequence variation in the DCM cohort using denaturing high-performance liquid chromatography (DHPLC) heteroduplex analysis (WAVE DHPLC System; Transgenomic; Omaha, NE). Because polymerase chain reaction reagents for optimal amplification of exon 1 were not compatible with DHPLC, Sanger sequencing was performed on all samples as well as on the 1-kb 5Ј untranslated region in 1 affected individual. Exon 2, containing the identified S102P variant, also was screened in 474 ethnically matched control samples. The buffer gradient and column melting temperatures for DHPLC were determined with Transgenomic Navigator software version 1.7.0 (build 25) and experimental optimization. Chromatographic elution profiles of samples yielding traces different from the wild-type homoduplex pattern were selected for Sanger sequencing.
Immunohistochemistry
Ventricular endomyocardial biopsy tissue from the proband was formalin fixed and paraffin embedded before sectioning at 4 m for immunohistochemical staining. Three additional paraffin-embedded specimens served as controls. Normal heart tissue was obtained at autopsy from the left ventricles of a female and a male individual, both of whom died of noncardiac causes. In addition, left ventricular tissue was available from an individual with DCM due to a mutation in TPM1. 37 Paraffin slides were deparaffinized and pretreated in a 97°C solution (1 mmol/L EDTA, pH 8.0) for 30 minutes using a PT Link (DAKO; Carpinteria, CA). Optimization of the antibody and the final staining was carried out by an automated immunohistochemistry staining machine (DAKO Autostainer Plus). GATAD1 protein expression was evaluated with a mouse monoclonal antihuman GATAD1 antibody recognizing amino acids 129 to 261 (Abcam; Cambridge, MA). The antibody was diluted 1:25 for a 30-minute incubation using ADVANCE, a highly sensitive 2-step polymer system (DAKO). A mouse monoclonal antihuman antibody against the ␣and ␥-isoforms of muscle actin (DAKO) was diluted 1:150 and incubated for 30 minutes using DAKO dual polymer chemistry. For both antibodies, the chromogen used for detection was diaminobenzidine (DAKO). A negative control underwent the same procedure but without the addition of primary antibody. All slides were counterstained with hematoxylin and cover slipped for microscopic examination.
Results
Family Phenotype
The proband (III.12) ( Figure 1 , Table) presented at age 50 years with heart failure and cardiomegaly. Her medical history was negative for hypertension, diabetes, and tobacco or alcohol use. Echocardiography was diagnostic for DCM, and angiography ruled out coronary artery disease. Left ventricular endomyocardial biopsy revealed moderate myocyte hypertrophy, mild focal interstitial fibrosis, and mild diffuse endocardial fibrosis, consistent with a chronic cardiomyopathy. Her medical therapy included digoxin, furosemide, carvedilol, enalapril, spironolactone, and warfarin (for apical thrombus). She has had no history of arrhythmia, and 24 years after her initial presentation, she is in New York Heart Association class II heart failure with moderate to severe left ventricular enlargement and an ejection fraction of 25%.
The extended family is of Norwegian ancestry with an initial history negative for cardiomyopathy, heart failure, and sudden death. However, the parents of the proband were first cousins (II.1 and II.2) who died at advanced ages without apparent heart disease, suggesting a recessive form of DCM. Screening echocardiograms were performed in 16 of her relatives, and genomic DNA samples were procured. Two of 8 asymptomatic siblings of the proband were found to have cardiomyopathy in the absence of established risk factors for coronary and myopathic heart disease. A sister (III.10) was given a diagnosis of DCM at age 53 years. Her treatment included furosemide, metoprolol, losartan, spironolactone, warfarin, and AV node ablation with pacemaker implantation for persistent atrial fibrillation. She remained in New York Heart Association class II heart failure 23 years after diagnosis, with mild left ventricular enlargement and an ejection fraction of 40%. A 57-year-old brother (III.6) was given a diagnosis of idiopathic left ventricular enlargement, a known intermediate phenotype of DCM, 1, 4, 24, 25 which was confirmed by a follow-up echocardiogram 3 years later. He was treated with furosemide, metoprolol, and captopril. At age 68 years, he had cardiomegaly on chest radiography and a borderline ejection fraction of 50% on left ventricular angiography. He died of cancer at age 73 years. The remaining 6 siblings (III.1-III.5, III.8), ages 55 to 81 years, had completely normal echocardiograms, and none developed heart failure over the 4 to 22 years of follow-up. DCM also was excluded in all 8 . Consistent with homozygous recessive inheritance, identical diseaseassociated haplotypes (boxed) are inherited by the 3 affected family members from their first-cousin parents. Recombination events account for homozygous inheritance of portions of the haplotype in an unaffected (III.4) and affected (III.6) individual, defining D7S669 as the upper-flanking marker. The lowerflanking marker, D7S515, is defined by heterozygous genotypes in all 3 affected individuals (III.6, III.10, and III.12). GATAD1 maps within this 24-Mb DCM locus. Presence of the identified GATAD1-S102P mutation is indicated by a plus symbol (ϩ) and its absence by a minus (Ϫ) symbol. Clinically affected individuals are homozygous for the mutation.
offspring of the 3 affected siblings, and none have developed heart failure over 20 years of follow-up. Although male-male transmission was not observed, X-linked recessive inheritance was effectively ruled out based on the milder cardiomyopathy phenotype in the brother compared with his affected sisters. In summary, the family history and clinical evaluations indicated that nonsyndromic DCM was inherited as an autosomal recessive trait.
DCM Locus Mapping
Genome-wide linkage analysis specifying a homozygous recessive mode of inheritance identified a DCM locus on chromosome arm 7q21 with a peak multipoint logarithm of the odds (LOD) score of 3.1 between markers D7S669 and D7S515 ( Figure 2 ). Construction of haplotypes revealed homozygosity for 2 adjacent short tandem repeat markers in the 3 affected siblings but none of the 6 unaffected siblings. Flanking markers defined a region of 24 Mb that encompassed 258 genes (Figure 1) . A more conservative approach, where the phenotype of III.6 was adjusted to uncertain, resulted in a peak multipoint LOD score of 1.9 at the same 7q21 locus (data not shown). In separate linkage analyses specifying a dominant mode of inheritance; 60%, 80%, or 100% penetrance; and classification of subject III.6 as affected or uncertain, no locus with a multipoint LOD score Ն1.3 (PՅ0.05) was identified.
Homozygosity Mapping
High-density homozygosity mapping revealed a contiguous block of homozygous SNVs at the 7q21 locus, verifying that this region harbored an autosomal recessive DCM gene and significantly narrowing the size of the critical region ( Figure  3 ). An identical block of 1900 homozygous SNVs spanning 15.9 Mb was identified at 7q21 in the 3 affected siblings. An unaffected individual (III.4) was homozygous for the identical haplotype over an 8.6-Mb portion of this region (1011 contiguous SNVs), thus refining the centromeric boundary of the critical region. Among the 5 other unaffected siblings, 4 were heterozygous for the DCM-associated haplotype, and 1 inherited no copies. The 7q21 locus was the only region of shared homozygosity among the 3 affected individuals. The more conservative approach, in which only the 2 affected sisters were analyzed, revealed 5 additional homozygous blocks on 4 chromosomes. However, each haplotype was shared by at least 1 unaffected sibling (online-only Data Supplement Table I ). Homozygosity mapping enabled a 3-fold reduction in the size of the 7q21 locus, a 7.3-Mb critical region comprising 61 gene candidates. Further analysis of the SNV chip data revealed no instances of copy number variants (ie, subchromosomal deletions or duplications) shared among the 3 affected individuals.
Exome Sequencing and Bioinformatics Analysis
Genomic DNA samples from 2 of the affected individuals (III.10 and III.12) were submitted for whole-exome sequenc-ing after targeted exome capture. Each sample was sequenced in 2 lanes of the same flow cell, yielding 65 million pairs of nucleotide sequences from paired-end, 76-bp reads. Data analysis determined that 86% of the sequence mapped to the genome, and 50% was found within targeted regions. Representation of the exome was the same in both individuals, with 73% and 92% coverage of the targeted regions demonstrating a minimal read depth of 20-fold and 5-fold, respectively. Detected SNVs and insertions and deletions were annotated and loaded onto a spreadsheet, enabling an iterative filtering process to identify the pathogenic mutation ( Figure  4 ). Largely because of the homozygous recessive mode of inheritance, extensive unbiased filtering was possible without taking into account the 7q21 critical region or predicting the functional impact of nonsynonymous variants. We first excluded SNVs reported in HapMap, 1000 Genomes, or 16 exomes of individuals sequenced in our core facility. We then filtered the remaining novel variants by removing synonymous SNVs, intergenic variants, and intronic variants not localized to splice sites. Nonsilent SNVs thus were defined as missense, nonsense, and insertion-deletion coding variants and variants residing within untranslated regions or canonical splice donor/acceptor sites. Based on the recessive mode of inheritance, the next filter excluded heterozygous SNVs. We subsequently narrowed the list of remaining homozygous SNVs to those shared by the affected sisters. The filtering process culminated in a restricted list of only 3 homozygous missense variants, each of which was verified by Sanger sequencing and absent from the Human Gene Mutation Database. Variants in SETD1A and MYLK3 were each localized to a region of chromosome 16 identified by affected sisters-only homozygosity mapping, but in both cases, a phenotypically normal elderly sibling (III.3) was homozygous for the variant (online-only Data Supplement Figure I) . These variants thus were ruled out as having a primary, causative role in autosomal recessive DCM, although a disease-modifying effect cannot be excluded. A solitary mutation in GATAD1 remained for which the 3 affected siblings were homozygous and which mapped to the 7q21 critical region. The 6 unaffected siblings were either heterozygous or homozygous for the normal allele. The 8 unaffected offspring of affected individuals were obligate heterozygous carriers of the mutation. The identified missense mutation was a c.304 TϾC nucleotide transition in exon 2 of GATAD1, encoding GATA zinc finger domaincontaining protein 1 ( Figure 5 ). The resultant S102P substitution replaces a polar hydroxyl serine with a nonpolar cyclic proline. No additional mutations in GATAD1 were identified in the coding region or 5Ј untranslated region of the proband. In addition to being absent from the large variant databases used in the filtering process, the mutation was not present in 474 healthy control samples (948 chromosomes) of similar ancestry. To determine whether heterozygous mutations in GATAD1 underlie autosomal dominant or sporadic DCM, the 5 exons of this gene were screened in 273 unrelated subjects. Two reported polymorphisms in exons 1 and 5 (G54S and R233W) were identified, but there were no instances of unreported nonsynonymous variants within GATAD1, indicating highly conserved nucleotide and protein sequences. Together with control samples, the S102P mutation was absent in a total of 1558 chromosomes. Furthermore, examination of the exome sequencing data did not reveal homozygous mutations in Ͼ30 genes previously associated with DCM. 6
GATAD1 Protein Localization
According to Gene Expression Omnibus array data, GATAD1 is ubiquitously expressed among various tissue types and in embryonic mouse hearts at all stages of development. To qualitatively verify cardiac expression, determine subcellular localization, and explore the mutation's potential effect on histology, we performed immunohistochemistry using a monoclonal antibody against GATAD1. Within healthy left ventricular tissue, GATAD1 localized to the nucleus and cytoplasm with a homogenous, striated staining pattern ( Figure 6A and 6B) . A similar staining pattern was seen in the left ventricular myocardium of a patient with genetically defined DCM 37 ( Figure 6C ). In contrast, homozygosity for the S102P in GATD1 resulted in a marked disturbance in its extranuclear distribution in the proband ( Figure 6D ). Actin staining of an adjacent tissue section ( Figure 6E ) was indistinguishable from control tissues, and complete absence of staining in the negative control lent further support to the specificity of the antibody (data not shown). Additionally, myocyte nuclei in the proband had a unique globular morphology, contrasting with the elongated spindle shape observed in the controls.
Discussion
DCM is characterized by marked genetic and clinical heterogeneity. 6 Knowledge of the molecular basis of this disorder continues to evolve with the identification of mutations in genes involved in distinct biological pathways. Here, we used synergistic genomic strategies for hypothesis-free disease gene discovery in a family with autosomal recessive DCM, leading to identification of a pathogenic homozygous mutation in GATAD1, encoding GATA zinc finger domaincontaining 1.
GATAD1 Is a Reader of the Histone Code
Histones are the fundamental building blocks of chromatin, proteins that package and condense DNA into structural units known as nucleosomes. Histone tails serve as targets for multiple posttranslational modifications, such To identify a pathogenic mutation that underlies autosomal recessive dilated cardiomyopathy, an iterative filtering process was applied to single-nucleotide variants and insertions and deletions identified in III.12 and III.10 by exome sequencing. The list of potential candidate genes was narrowed to 3, each harboring a novel, nonsilent, homozygous single-nucleotide variant shared by the affected sisters. Only 1 of these-GATAD1-S102P-mapped to the critical region on chromosome arm 7q21.
as methylation, acetylation, and phosphorylation, which modulate epigenetic gene expression. Over the past 10 years, increased knowledge of the histone code has revealed the biochemical complexity of gene regulation by multiple protein readers known to interact with individual modifications. 38 GATAD1, a 269-amino acid protein with ubiquitous tissue expression, was recently shown to assemble with proteins of a chromatin complex that specifically interact with a prototypic epigenetic mark-H3K4Me3 (trimethylation of the fourth residue [lysine] on histone 3). 39 Moreover, a role for H3K4Me3 in heart failure has been implicated based on a unique epigenetic profile in left ventricular myocardium of patients with DCM compared with normal heart tissue. 40 Although the specific effects of GATAD1-S102P on nucleosome protein interactions and downstream gene expression are unknown, the mutation leads to a heart-specific phenotype and implicates epigenetic dysregulation as a novel basis for human DCM. Functional studies will be required to gain further insight into the mechanisms by which the GATAD1 mutation causes DCM. GATAD1 mutations appear to be a rare cause for DCM, yet defects within other nucleosomeinteracting proteins may prove to be important in disease pathogenesis.
Epigenetics and DCM
The link between epigenetics and myopathic heart failure has been well established in genetically modified mouse models, which is best exemplified by dysregulation of histone deacetylases. 41 In particular, conditional knockout of both Hdac1 and Hdac2 in the murine heart results in DCM. 42 Modified conditional knockouts that leave one allele of either Hdac1 or Hdac2 intact result in phenotypically normal mice, demonstrating a capacity to compensate for haploinsufficiency. Remarkably, human HDAC1 and HDAC2 are binding partners with GATAD1, 39 lending further support to perturbed nucleosome protein interactions in the pathogenesis of DCM.
Genotype-Phenotype Correlation
Unlike early onset, clinically aggressive heart failure reported in rare families with proven 43 or suspected 44, 45 autosomal recessive DCM, the phenotype in the present family was similar to patients with autosomal dominant or sporadic forms of disease. In fact, the only clues for recessive inheritance were consanguinity, lack of heart failure in the ancestors of affected family members by history, and lack of DCM in offspring of affected family members by echocardiographic screening. Variable disease expression is a wellrecognized phenomenon in familial DCM, attributable to modifier genes, environmental variables, or epigenetic factors. An intriguing clinical observation within the family in the present study is the overt DCM phenotype in the affected sisters versus the intermediate phenotype of left ventricular enlargement with preserved ejection fraction in the male sibling. This may be partially explained by differential cardiac expression of GATAD1 observed in men and women. Indeed, GATAD1 was one of few autosomal genes found to be more highly expressed in women than in men with DCM and new-onset heart failure (Ͼ1.6-fold change). 46 We have clearly shown that the GATAD1-S102P mutation is recessive, as 13 heterozygous carriers had normal cardiac phenotypes. Like Hdac1 and Hdac2, this indicates that GATAD1 can carry out its regulatory role with only 1 wild-type allele.
Disrupted Localization of GATAD1-S102P
Our immunohistochemistry experimentation confirmed that GATAD1 is expressed in left ventricular myocytes. Moreover, the GATAD1-S102P mutant protein was detected in the proband's myocardium, ruling out deficiency of GATAD1 as a consequence of the underlying homozygous mutation. The similarity of GATAD1 staining patterns and nuclear morphology in TPM1-DCM and normal control tissues, distinct from the proband, indicates that GATAD1-S102P has a mutation-specific effect. On the other hand, abnormal nuclear morphology is a hallmark of DCM caused by knockout of LMNA, a gene that encodes a structural protein of the nuclear membrane. 47 Previous work 36, 39, 40, 46 together with the present immunohistochemistry findings strongly support a role for GATAD1 in nuclei of cardiac myocytes. Extranuclear staining raises the further possibility of a broader role for GATAD1 in the heart.
Synergy of Locus Mapping and Exome Sequencing
Although genome-wide linkage analysis and homozygosity mapping identified a single locus for autosomal recessive DCM on chromosome arm 7q21, 61 positional candidate genes localized to the critical region. GATAD1, which is functionally distinct from known DCM genes, was not readily apparent as a compelling candidate. Exome sequencing of 2 affected family members and the iterative filtering process enabled us to analyze the entire exome and narrow the number of potential candidates to only 3 genes before taking into account the mapping information. Filtering was significantly aided by the family's homozygous recessive mode of inheritance, allowing a 10-fold reduction in candidate variants in step 3 (Figure 4 ). Successful identification of a pathogenic mutation in the family by whole-exome sequencing thus proved to be minimally reliant on positional information. However, the mapping data provided independent verification that the disease gene resided within the 7q21 locus. Moreover, extensive phenotypic characterization of 17 family members enabled unambiguous determination of an autosomal recessive mode of inheritance and robustly demonstrated cosegregation of homozygosity for the GATAD1 mutation with DCM.
Exome sequencing is poised to have a transformative impact on novel DCM gene discovery, yet a major challenge is the large number of novel variants present in individual exomes. In families with autosomal dominant DCM attributable to unidentified heterozygous mutations, additional filtering criteria likely would be required to identify disease-causing mutations (eg, exclusion of variants in genes with low cardiac expression levels and exclusion of gene variants predicted to have nondamaging effects on protein structure and function). 19 However, the most robust genetic evidence for causality would be derived from comparative analyses of exome sequencing data for several affected family members and complementary whole-genome mapping data to narrow the list of candidate variants to a discrete chromosomal locus. Figure 6 . Immunohistochemistry was performed with a monoclonal antibody against GATAD1 on left ventricular tissue from 4 individuals. Normal tissue from a male individual (A) and a female individual (B) show nuclear staining of GATAD1 with a homogeneous striated pattern in the extranuclear space similar to what was noted in tissue from an individual with dilated cardiomyopathy due to a mutation in TPM1 (C). In contrast, GATAD1 in biopsy tissue from the proband shows an abnormal staining pattern (D). Although there is still nuclear localization, extranuclear distribution of GATAD1 is perturbed, whereas actin staining of an adjacent section (E) was indistinguishable from normal controls (data not shown). In addition, the globular morphology of nuclei is unique from the spindle shape observed in control tissue. Magnification ϫ630.
